NCT02076997View on ClinicalTrials.gov

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

May 30, 2017

Study Completion Date

May 10, 2019

Conditions
Cancer
Interventions
DRUG

Methotrexate

"Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."

Trial Locations (1)

77030

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Texas Children's Cancer Center

OTHER

lead

Baylor College of Medicine

OTHER

NCT02076997 - Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate | Biotech Hunter | Biotech Hunter